A Potentially Deleterious New CYP2C9 Polymorphism Identified in an African American Patient With Major Hemorrhage on Warfarin Therapy

Blood Cells, Molecules, and Diseases - United States
doi 10.1016/j.bcmd.2008.10.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Significant Weight Gain in CLL Patients Treated With Ibrutinib: A Potentially Deleterious Consequence of Therapy

American Journal of Hematology
Hematology
2019English

CYP2C9 Genetic Polymorphisms and Warfarin

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2004English

Patient Time Requirements for Anticoagulation Therapy With Warfarin

Medical Decision Making
Health Policy
2009English

Time-Dependent Inhibition (TDI) of CYP3A4 and CYP2C9 by Noscapine Potentially Explains Clinical Noscapine-Warfarin Interaction

British Journal of Clinical Pharmacology
Pharmacology
2010English

An African American Perspective on the New Testament Commentary

HTS Teologiese Studies / Theological Studies
Religious Studies
2010English

Management of Intracranial Hemorrhage During Anticoagulant Therapy With Warfarin or Novel Anticoagulants

Clinical Neurology
Neurology
2012English

The Impact of Aripiprazole on INR in a Psychotic Patient During Warfarin Therapy

Psychiatry and Clinical Psychopharmacology
PsychiatryMental HealthPharmacology
2018English

A Haplotype of CYP2C9 Associated With Warfarin Sensitivity in Mechanical Heart Valve Replacement Patients

British Journal of Clinical Pharmacology
Pharmacology
2010English

Acute Mesenteric Ischemia in an African American Patient With Heterozygous Factor v Leiden Deficiency

Journal of Community Hospital Internal Medicine Perspectives
Internal Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy